var data={"title":"Oxytocin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxytocin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6711?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxytocin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxytocin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709190\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, oxytocin is not indicated for elective induction of labor.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205493\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pitocin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205494\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Oxytocin for injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205529\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Oxytocic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205497\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage is determined by uterine response and must be individualized and initiated at a very low level for each patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Induction or stimulation of labor:</b> IV: Administration requires the use of an infusion pump. The ideal dosing regimen has not been determined (Leduc 2013) and various protocols are available (ACOG 2009; Leduc 2013; Wei 2010). Discontinue the oxytocin infusion immediately in the event of uterine hyperactivity and/or fetal distress. If uterine contractions become too powerful, the infusion can be stopped abruptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 0.5 to 1 milliunits/minute; gradually increase dose in increments of 1 to 2 milliunits/minute every 30 to 60 minutes until desired contraction pattern is established; dose may be decreased by similar increments after desired frequency of contractions is reached and labor has progressed to 5 to 6 cm dilation. Higher infusion rates may be needed prior to term due to a lower sensitivity of the uterus. Infusion rates up to 6 milliunits/minute provide oxytocin levels similar to those with spontaneous labor; rates &gt;9 to 10 milliunits/minute are rarely required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Low-dose regimen (off-label dose): Initial 0.5 to 2 milliunits/minute, incrementally increase by 1 to 2 milliunits/minute every 15 to 40 minutes (ACOG 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High-dose regimen (off-label dose): Initial 6 milliunits/minute, incrementally increase by 3 to 6 milliunits/minute every 15 to 40 minutes. Reduce the incremental increase to 3 milliunits/minute if hyperstimulation occurs; reduce the incremental increase to 1 milliunit/minute for recurrent hyperstimulation (ACOG 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Postpartum uterine bleeding:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 10 units after delivery of the placenta</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 to 40 units added to a running infusion solution depending on amount of infusion fluid remaining (maximum: 40 units in 1,000 mL of IV fluid); adjust infusion rate to sustain uterine contraction and control uterine atony. Slow IV injections (5 or 10 units over 1 minute) are preferred for women without cardiovascular risk factors although rapid injections may be considered; very slow injections (&ge;5 minutes) are preferred for women with cardiovascular risk factors (Sentilhes 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adjunctive treatment of abortion:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Incomplete, inevitable, or elective abortion: 10 units as an IV infusion after suction or a sharp curettage (used to help contract the uterus)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Midtrimester elective abortion: 10 to 20 <b>milli</b>units/minute; maximum total dose: 30 units/12 hours (may decrease injection to abortion time)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123830\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123831\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205472\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pitocin: 10 units/mL (1 mL, 10 mL, 50 mL [DSC]) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 units/mL (1 mL, 10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 units/1000 mL in Dextrose 5% (1000 mL); 10 units/1000 mL in Dextrose 5% and Lactated Ringers (1000 mL); 10 units/1000 mL in Lactated Ringers (1000 mL); 10 units/500 mL in Dextrose 5% and Lactated Ringers (500 mL); 10 units/500 mL in Lactated Ringers (500 mL); 10 units/500 mL in NaCl 0.9% (500 mL); 15 units/250 mL in Dextrose 5% (250 mL); 15 units/250 mL in Lactated Ringers (250 mL); 15 units/250 mL in NaCl 0.9% (250 mL); 15 units/500 mL in Dextrose 5% and Lactated Ringers (500 mL [DSC]); 15 units/500 mL in Lactated Ringers (500 mL [DSC]); 20 units/1000 mL in Dextrose 5% (1000 mL); 20 units/1000 mL in Dextrose 5% and Lactated Ringers (1000 mL); 20 units/1000 mL in Lactated Ringers (1000 mL); 20 units/1000 mL in NaCl 0.45% (1000 mL); 20 units/1000 mL in NaCl 0.9% (1000 mL); 20 units/500 mL in Dextrose 5% and Lactated Ringers (500 mL); 20 units/500 mL in Lactated Ringers (500 mL); 30 units/1000 mL in Dextrose 5% and Lactated Ringers (1000 mL); 30 units/1000 mL in Lactated Ringers (1000 mL); 30 units/1000 mL in NaCl 0.9% (1000 mL); 30 units/500 mL in Dextrose 5% and Lactated Ringers (500 mL); 30 units/500 mL in Lactated Ringers (500 mL); 30 units/500 mL in NaCl 0.9% (500 mL); 40 units/1000 mL in Dextrose 5% (1000 mL [DSC]); 40 units/1000 mL in Dextrose 5% and Lactated Ringers (1000 mL); 40 units/1000 mL in NaCl 0.9% (1000 mL); 40 units/500 mL in Lactated Ringers (500 mL); 60 units/1000 mL in NaCl 0.9% (1000 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205457\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205474\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Induction or stimulation of labor: Administer as an IV infusion (drip method) by use of an infusion pump; accurate control of the rate of infusion flow is essential.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Incomplete or inevitable abortion: Administer by IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postpartum uterine bleeding: Administer by IV or IM.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132765\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during administration (NIOSH 2016). Premixed solutions may be excluded from some hazardous drug handling requirements. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205473\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antepartum:</b> Induction of labor in patients with a medical indication (eg, Rh problems, maternal diabetes, preeclampsia, at or near term); stimulation or reinforcement of labor (as in selected cases of uterine inertia); adjunctive therapy in management of incomplete or inevitable abortion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postpartum:</b> To produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205536\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205464\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia (including premature ventricular contraction), hypertension, subarachnoid hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Hypertonia (uterine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Water intoxication (severe water intoxication with seizure and coma is associated with a slow oxytocin infusion over 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Postpartum hemorrhage, tetanic uterine contractions, uterine rupture, uterine spasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Pelvic hematoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205477\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to oxytocin or any component of the formulation; significant cephalopelvic disproportion; unfavorable fetal positions or presentations (such as transverse lies); fetal distress when delivery is not imminent; hypertonic or hyperactive uterus; contraindicated vaginal delivery (invasive cervical cancer, active genital herpes, prolapse of the cord, cord presentation, total placenta previa, or vasa previa); obstetrical emergencies where surgical intervention is favored; where adequate uterine activity fails to achieve satisfactory progress</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205461\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antidiuretic effect: May produce intrinsic antidiuretic effect (ie, water intoxication). Severe water intoxication with convulsions, coma, and death may occur, particularly with large doses (40 to 50 milliunits/minute) or when given as a slow infusion over 24 hours and if the patient is receiving fluids by mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Arrhythmias, hypotension, myocardial ischemia, peripheral vasodilation, and tachycardia have been reported following administration. The risk of adverse events is influenced by dose and route of administration and is increased in women with cardiovascular disease. Use with extreme caution in hemodynamically unstable patients (Dyer 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maternal deaths: Maternal deaths caused by hypertensive episodes, subarachnoid hemorrhage, or rupture of the uterus and fetal deaths have occurred with oxytocic medications when used for induction of labor or for augmentation in the first and second stages of labor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Uterine effects: High doses or hypersensitivity to oxytocin may cause uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: To be used for medical rather than elective induction of labor.</b> Oxytocin is used to initiate or improve uterine contractions in order to achieve a vaginal delivery; it should only be used when medically needed for fetal or maternal reasons. Medical indications for labor induction may include Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interest of mother or fetus, or premature rupture of membranes when delivery is indicated. Use is generally not recommended in the following conditions: Fetal distress, hydramnios, partial placenta previa, prematurity, borderline cephalopelvic disproportion, or conditions where there is a predisposition for uterine rupture (eg, previous major surgery on cervix or uterus, cesarean section, overdistention of the uterus, grand multiparity, past history of uterine sepsis or traumatic delivery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Abortion: For the adjunctive management of abortion in the first trimester, curettage is generally considered primary therapy. Oxytocin infusion in second trimester abortion will often be effective; however, other therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: IV preparations should be administered by adequately trained individuals familiar with its use and able to identify complications; continuous observation is necessary for all patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299808\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205466\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9734&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Carboprost Tromethamine: May enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dinoprostone: May enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. Management: Concomitant use of dinoprostone and oxytocin is not recommended. If used sequentially, monitor uterine activity closely. Administer oxytocin 30 minutes after removing dinoprostone vaginal insert and 6 to 12 hours after the application of dinoprostone gel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Nasal): Oxytocin may enhance the hypertensive effect of EPHEDrine (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): Oxytocin may enhance the hypertensive effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemeprost: May enhance the adverse/toxic effect of Oxytocin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiSOPROStol: May enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced. Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin.  Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205479\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: To be used for medical rather than elective induction of labor.</b> Small amounts of exogenous oxytocin are expected to reach the fetal circulation. When used as indicated, teratogenic effects would not be expected. Nonteratogenic adverse reactions are reported in the neonate as well as the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205480\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous oxytocin mediates milk ejection. Administration of exogenous oxytocin may disrupt the initiation of breastfeeding (Buckley 2015). Skin-to-skin contact between mother and baby facilitates the release of endogenous oxytocin and the establishment of the milk ejection reflex (ABM 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205470\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fluid intake and output during administration, uterine activity (tonus, amplitude, and frequency of contractions), maternal blood pressure; fetal heart rate in relation to uterine contractions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205460\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oxytocin stimulates uterine contraction by activating G-protein-coupled receptors that trigger increases in intracellular calcium levels in uterine myofibrils. Oxytocin also increases local prostaglandin production, further stimulating uterine contraction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205476\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Uterine contractions: IM: 3 to 5 minutes; IV: ~1 minute </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM: 2 to 3 hours; IV: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1 to 6 minutes; decreased in late pregnancy and during lactation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (small amount unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323589\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxytocin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 units/mL (1 mL): $0.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxytocin-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10UNT/L 5% (1000 mL): $11.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15UT/250ML 5% (250 mL): $10.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNT/L 5% (1000 mL): $15.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxytocin-Dextrose-Lact Ringers Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10UNIT/L 5% (1000 mL): $11.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10UT/500ML 5% (500 mL): $11.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNIT/L 5% (1000 mL): $10.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UT/500ML 5% (500 mL): $15.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30UNIT/L 5% (1000 mL): $13.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30UT/500ML 5% (500 mL): $13.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40UNIT/L 5% (1000 mL): $13.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxytocin-Lactated Ringers Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10UNIT/500ML (500 mL): $11.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10UNIT/L (1000 mL): $13.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15UNIT/250ML (250 mL): $11.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNIT/500ML (500 mL): $14.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNIT/L (1000 mL): $11.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30UNIT/500ML (500 mL): $12.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30UNIT/L (1000 mL): $13.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40UNIT/500ML (500 mL): $22.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40UNIT/L (1000 mL): $14.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxytocin-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10UT/500ML 0.9% (500 mL): $14.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15UT/250ML 0.9% (250 mL): $13.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNIT/L 0.45% (1000 mL): $12.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNT/L 0.9% (1000 mL): $14.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30UNIT/L 0.9% (1000 mL): $14.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30UT/500ML 0.9% (500 mL): $13.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40UNIT/L 0.9% (1000 mL): $19.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60UNIT/L 0.9% (1000 mL): $34.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pitocin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 units/mL (10 mL): $12.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205481\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ao Sai Juo Xing (CN);</li>\n      <li>Cetocin (PH);</li>\n      <li>Evatocin (LK, PH);</li>\n      <li>Induxin (ID);</li>\n      <li>Litocin (TW);</li>\n      <li>NeOxyn (PH);</li>\n      <li>Ocin (BD);</li>\n      <li>Octocin (TH);</li>\n      <li>Ofost (CZ);</li>\n      <li>Oksitocins (EE);</li>\n      <li>Oxitol (PY);</li>\n      <li>Oxitone (AE, BH, CY, IL, IQ, IR, KW, LB, LY, OM, PH, QA, SA, SY, YE);</li>\n      <li>Oxocin (TW);</li>\n      <li>Oxyla (ID, MY);</li>\n      <li>Partocon INJ (FI);</li>\n      <li>Pitocin (BD, EC);</li>\n      <li>Pitocin INJ (IN);</li>\n      <li>Pitogin (ID);</li>\n      <li>Piton S INJ (AE, BH, CY, EG, IQ, IR, KW, LB, LY, NL, OM, QA, SA, SY, YE);</li>\n      <li>Protocin (ID);</li>\n      <li>Santocyn (ID);</li>\n      <li>Solvoxine (PH);</li>\n      <li>Synthetic Oxytocin INJ (IN);</li>\n      <li>Syntocinon (CL, CR, DK, DO, EG, GT, HN, HR, IS, JO, KW, LU, MT, NI, PA, PT, QA, SI, SV, TR, VN);</li>\n      <li>Syntocinon INJ (AR, AT, AU, BE, BF, BJ, BR, CH, CI, DE, ES, ET, FI, FR, GB, GH, GM, GN, HK, ID, IE, IT, KE, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NZ, PE, PH, PK, PL, PY, SC, SD, SE, SG, SL, SN, TN, TZ, UG, UY, VE, ZA, ZM, ZW);</li>\n      <li>Syntocinon Spray (AT, CH, NO, PL, SE);</li>\n      <li>Tiacinon (ID);</li>\n      <li>Udoxan (MY);</li>\n      <li>Vitocin (LK);</li>\n      <li>Xitocin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Xytocin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Academy of Breastfeeding Medicine (ABM) Protocol Committee. ABM Clinical Protocol #9: Use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First Revision January 2011). <i>Breastfeed Med</i>. 2011;6(1):41-49. doi: 10.1089/bfm.2011.9998.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/21332371/pubmed\" target=\"_blank\" id=\"21332371\">21332371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins - Obstetrics, &quot;ACOG Practice Bulletin No.107: Induction of Labor,&quot;<i>Obstet Gynecol</i>, 2009, 114(2 Pt 1):386-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/19623003/pubmed\" target=\"_blank\" id=\"19623003\">19623003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckley SJ. Executive summary of hormonal physiology of childbearing: evidence and implications for women, babies, and maternity care. <i>J Perinat Educ</i>. 2015;24(3):145-153. doi: 10.1891/1058-1243.24.3.145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/26834435/pubmed\" target=\"_blank\" id=\"26834435\">26834435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. <i>Curr Opin Anaesthesiol</i>. 2011;24(3):255-261. doi: 10.1097/ACO.0b013e328345331c.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/21415725/pubmed\" target=\"_blank\" id=\"21415725\">21415725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leduc D, Biringer A, Lee L, Dy J; Clinical Practice Obstetrics Committee; Special Contributors. Induction of labour. <i>J Obstet Gynaecol Can</i>. 2013;35(9):840-857. doi: 10.1016/S1701-2163(15)30842-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/24099451/pubmed\" target=\"_blank\" id=\"24099451\">24099451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxytocin injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; June 2011</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pitocin (oxytocin) [prescribing information]. Spring Valley, NY: Par Pharmaceutical; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajan PV and Wing DA, &quot;Postpartum Hemorrhage: Evidence-Based Medical Interventions for Prevention and Treatment,&quot; <i>Clin Obstet Gynecol</i>, 2010 53(1):165-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/20142654/pubmed\" target=\"_blank\" id=\"20142654\">20142654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sentilhes L, Vayssi&egrave;re C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). <i>Eur J Obstet Gynecol Reprod Biol</i>. 2016;198:12-21. doi: 10.1016/j.ejogrb.2015.12.012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/26773243/pubmed\" target=\"_blank\" id=\"26773243\">26773243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wei SQ, Luo ZC, Qi HP, et al, &quot;High-Dose vs Low-Dose Oxytocin for Labor Augmentation: A Systematic Review,&quot; <i>Am J Obstet Gynecol</i>, 2010, 203(4):296-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxytocin-drug-information/abstract-text/20451894/pubmed\" target=\"_blank\" id=\"20451894\">20451894</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9734 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709190\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F205493\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F205494\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F205529\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F205497\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22123830\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22123831\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F205472\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F205457\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F205474\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132765\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F205473\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F205536\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F205464\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F205477\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F205461\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299808\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F205466\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F205479\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F205480\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F205470\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F205460\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F205476\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323589\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F205481\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9734|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxytocin-patient-drug-information\" class=\"drug drug_patient\">Oxytocin: Patient drug information</a></li></ul></div></div>","javascript":null}